# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Truist Securities analyst Barry Jonas maintains Ballys (NYSE:BALY) with a Buy and raises the price target from $14 to $16.
The special committee of independent and disinterested directors (the "Special Committee") of Bally's Corporation (...
The Board of Directors of Bally's Corporation (NYSE:BALY) today announced that it has formed a special committee of indepen...
Shares of Mesoblast Limited (NASDAQ: MESO) rose sharply during Monday’s session after the company announced FDA support of an ...
- SEC Filing On March 11, 2024, Standard General delivered a non-binding letter (the "Proposal Letter") to the board of...
Stifel analyst Jeffrey Stantial maintains Ballys (NYSE:BALY) with a Hold and lowers the price target from $13 to $11.